• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Alfred Romann

Alfred Romann

Articles

ARTICLES

China indicts two GSK investigators linked to bribery scandal

July 15, 2014
By Alfred Romann
HONG KONG – China has indicted two investigators linked to the bribery scandal that has rocked Glaxosmithkline plc. The couple – 58-year-old British man Peter William Humphrey and his 61-year-old American Chinese wife Yu Yingzeng – was arrested in Shanghai last August.
Read More

Better devices could drive market for biosimilars

June 11, 2014
By Alfred Romann
HONG KONG – Over the next decade, competition for market share between biosimilar products and their originator drugs is likely to grow fierce, but price differentiation may not be enough to ensure sales.
Read More

Better devices could drive market for biosimilars

June 6, 2014
By Alfred Romann
HONG KONG – Over the next decade, competition for market share between biosimilar products and their originator drugs is likely to grow fierce, but price differentiation may not be enough to ensure sales.
Read More

Korea sets sights on biopharma powerhouse status by 2020

June 4, 2014
By Alfred Romann
SEOUL, South Korea – With one eye firmly planted on future economic growth, South Korea is taking steps to boost its biotechnology industry by putting resources into a wide range of traditional and emerging subsectors from biosimilars to stem cell treatments.
Read More

Biosimilars players will likely consolidate; sales potential still unknown

June 4, 2014
By Alfred Romann
SEOUL, South Korea – Promising as the biosimilar market appears today, a consolidation that leaves only a handful of global players may be inevitable and the prospects may not be as rosy as they seem, said drug company executives at Bio Korea 2014.
Read More

Korea sets sights on biopharma powerhouse status by 202

May 30, 2014
By Alfred Romann
SEOUL, South Korea – With one eye firmly planted on future economic growth, South Korea is taking steps to boost its biotechnology industry by putting resources into a wide range of traditional and emerging subsectors from biosimilars to stem cell treatments.
Read More

Biosimilars players will likely consolidate; sales potential still unknown

May 29, 2014
By Alfred Romann
SEOUL, South Korea – Promising as the biosimilar market appears today, a consolidation that leaves only a handful of global players may be inevitable and the prospects may not be as rosy as they seem, said drug company executives at Bio Korea 2014.
Read More

India looking at noncommercial use for BMS' dasatinib

May 14, 2014
By Alfred Romann
India is considering waiving a global patent for cancer drug dasatanib under provisions of the country's Patent Act that allow it to make the move for public noncommercial use.
Read More

India looking at noncommercial use for BMS' dasatinib

May 9, 2014
By Alfred Romann
India is considering waiving a global patent for cancer drug dasatanib under provisions of the country's Patent Act that allow it to make the move for public noncommercial use.
Read More

Transgene, Sillajen, Lee’s partner to bring liver cancer immunotherapy forward

April 2, 2014
By Alfred Romann
HONG KONG – A Hong Kong-based biotechnology company that specializes in in-licensing products for marketing in China will work with a partner in South Korea and one in Europe in a late-stage clinical development program for the oncolytic immunotherapy Pexa-Vec (JX-594/TG6006).
Read More
View All Articles by Alfred Romann

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 11, 2025.
  • Antibodies

    Abbvie gains rights to IGI’s trispecific ISB-2001 in $1.9B+ deal

    BioWorld
    Nearly six years after Ichnos Sciences Inc. launched operations, a subsidiary of the now-named Ichnos Glenmark Innovation (IGI) Inc. has signed with Abbvie Inc. a...
  • PTAB hands Exact a loss in Geneoscopy patent dispute

    BioWorld MedTech
    The med tech patent wars opened a new front in the region of screening tests for colorectal cancer, pitting Exact Sciences Corp., of Madison, Wisc., against St....
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 8, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe